What are the advertising rules for compounded GLP-1 medications?

FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing. The semaglutide and tirzepatide shortages that allowed wide compounding have been declared resolved, and the grace periods have closed. Marketing must start there, because advertising a product that cannot lawfully be supplied is a problem itself.

The FDA's compounding policy page for GLP-1s explains the rules that now apply. State-licensed pharmacies and physicians compounding under section 503A generally may not compound drugs that are "essentially a copy" of a commercially available approved product, unless a prescriber documents a significant difference for an identified patient. Outsourcing facilities under section 503B generally cannot compound from bulk semaglutide or tirzepatide, because neither is on the 503B bulks list or the shortage list.

The FDA's page on concerns with unapproved GLP-1 drugs adds that salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients from the approved drugs, and that FDA is not aware of any lawful basis for compounding with them. It also lists warning signs for consumers, including claims that a compounded drug is the same as an approved drug and unusually deep discounts. Those warning signs read like a list of ad claims to avoid.

Describe the medical program, not a drug that sounds like a brand product. Say the medication is compounded, that compounded drugs are not FDA-approved, that a licensed clinician decides whether it is appropriate, and which licensed pharmacy prepares it. Put this information where it is read, close to the price and the main claim.

Copy rules worth writing down

1. Name the product accurately: "compounded semaglutide" or "compounded tirzepatide", never a brand name or a lookalike.
2. Put the status near the claim: a short line such as "Compounded medications are not FDA-approved" next to the offer, not only in an FAQ.
3. Make the clinician the decision-maker: "if your clinician determines it is appropriate", not "get your GLP-1 today".
4. Name the pharmacy: who compounds the medication and where it is licensed.
5. Include safety information: balanced, close to the benefit language and in plain words.
6. Do not market around the rules: "personalized dose" is a clinical decision documented by a prescriber, not a marketing angle that makes a copy lawful.

Email, text and sales scripts

FDA letters have cited website claims, but the same rules reach every channel. Nurture emails, text reminders and the scripts used by intake or sales staff often drift into shorthand such as "it's the same as the brand" or "basically the generic". Review these with the same claims library as ads. Train staff to answer price and comparison questions with the approved line, and to hand clinical questions to a clinician.

What to lead with instead

Patients choosing a weight-management program care about the clinician, the follow-up, nutrition and lifestyle support, and the total cost. Those are honest, supportable messages. A program that leads with clinical oversight usually needs fewer risky claims to convert.

Our med spa weight-loss and GLP-1 marketing guide shows how clinics position these programs locally.

Ad platforms add their own rules: prescription drug and telemedicine advertising usually requires certification, and some platforms restrict or prohibit promotion of compounded or unapproved drugs. Creators add disclosure duties. FDA's September 9, 2025 crackdown on deceptive drug advertising named undisclosed paid influencer promotion as a concern. Check each platform's current policy before every launch.

Creator and affiliate content

Under the FTC Endorsement Guides, anyone paid or given free services to promote a GLP-1 program has a material connection to disclose clearly, in the content itself. The company is responsible for what its creators say. That makes creator content about compounded GLP-1s especially risky, because a creator's casual "it's the same thing, just cheaper" is precisely the sameness claim FDA has flagged.

• Brief creators with approved wording and a list of banned phrases.
• Prohibit any discussion of dosing, side-effect management or switching from an approved drug.
• Pre-approve every post, not just a sample, for this category.
• Monitor comments and stop creators from answering medical questions.

Search campaigns

Bidding on brand-name drug terms and sending that traffic to a compounded-drug offer is where sameness implications often arise. If you bid on those terms at all, the landing page must make the compounded, not-FDA-approved status unmistakable before any price or call to action.

Run a full audit now, then a lighter monthly check, because FDA has been issuing letters in waves. Start with every live asset: ads, landing pages, emails, texts, creator posts, review replies and sales scripts. Remove anything with sameness language, implied approval, borrowed trial data or unsupported results, and confirm the supply chain is lawful.

Audit checklist

1. Supply: can your pharmacy partner lawfully compound what you advertise under current FDA policy?
2. Naming: is the product called "compounded" everywhere, with no brand names or lookalikes?
3. Status line: does every asset say compounded drugs are not FDA-approved, near the claim?
4. Source: is the compounding pharmacy named?
5. Claims: are all outcome claims supported for the product as sold, with typical-results context?
6. Creators: are posts pre-approved and disclosures in the content itself?
7. Pricing: is total cost clear and consistent everywhere?
8. Privacy: are tracking pixels kept off intake and authenticated pages?

Who should own the process

Give one named person authority to pause any campaign. Pair them with a clinical reviewer for medical accuracy and with outside counsel for drug-promotion and compounding questions. Keep an approval log showing who signed off each asset and on what date. If a warning letter arrives, that log shows what was live, when, and what you changed in response.

The broader rules for virtual care marketing are in our guide to DTC telehealth marketing compliance. This page is a marketing overview, not legal advice; confirm specifics with healthcare counsel.

Where a fractional CMO fits

Santosh Reddy, Partner, Ichelon Consulting US, works with weight-management and telehealth companies as a fractional CMO, owning the claims library, review chain and channel plan. Plans run $1,000/month (Advisory), $1,500/month (Growth) and $2,000/month (Embedded), with execution scoped separately. Read about Santosh Reddy or book a call with the US team. We sign a BAA with every US client.